EUVIMEDOpdag EUVIMED
Crossref

Lysosome-Targeting Nanochimeras Attenuating Liver Fibrosis by Interconnected Transforming Growth Factor-β Reduction and Activin Receptor-Like Kinase 5 Degradation

Hanshu Liu, Yingqiu Qi iD, Longdi Wang, Yana Zhang, Hanqing Chen, Ying Zhao, Huan Min iD, Guangjun Nie iD, Hongxia Liang iD

ACS Nano · 2025

DOI: 10.1021/acsnano.5c00985 ↗

At a glance

Journal article in ACS Nano, 2025. Written by Hanshu Liu and 8 co-authors. Institution: Department of Infectious Disease and Hepatology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. Major MEDLINE topics: Liver Cirrhosis, Lysosomes, Transforming Growth Factor beta, Nanoparticles. Cited 23 times so far (Crossref); 48 references. Funded by: Ministry of Science and Technology of the People's Republic of China, Zhengzhou University, National Natural Science Foundation of China.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Liver fibrosis, characterized by excessive extracellular matrix (ECM) deposition, is predominantly driven by activated hepatic stellate cells (HSCs) through the TGF-β-Smad2/3 signaling pathway. A critical barrier to effective treatment has been the compensatory upregulation of the receptors, which often limits the efficacy of targeted TGF-β inhibition strategies. Our current study introduces a lysosomal targeting degradation chimera (MAP) composed of an antioxidative polydopamine (PDA) nanoparticle conjugated to the ligands specifically targeting ALK5, a TGF-β receptor I, and cation-independent mannose 6-phosphate receptor (CI-M6PR). Notably, CI-M6PR is highly upregulated on the surface of the activated HSCs. These MAPs preferentially accumulated in the fibrotic liver tissues, reduced TGF-β production by scavenging reactive oxygen species, and simultaneously recognized the activated HSCs to facilitate targeted lysosomal degradation of ALK5. The interconnected dual-enhanced mechanisms effectively inhibited the TGF-β-Smad2/3 signaling pathway in HSCs, thus diminishing ECM secretion and attenuating liver fibrosis. Together, the current findings, substantiated by in vitro and in vivo studies, demonstrate potent antifibrotic capacities of MAPs, marking an essential advancement in lysosome-targeting degradation technology for liver fibrosis treatment and expanding potential therapeutic options for this intractable condition.

Subjects

MeSH terms (MEDLINE)

Liver CirrhosisLysosomesTransforming Growth Factor betaNanoparticlesReceptor, Transforming Growth Factor-beta Type IAnimalsMiceHepatic Stellate CellsPolymersHumansIndolesSignal TransductionMaleMice, Inbred C57BL

Author keywords

CI-M6PRTGF-βhepatic stellate cellsliver fibrosislysosome-targeting degradation

Substances

Transforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type IPolymersIndolespolydopamine

Authors and institutions

  • Department of Infectious Disease and Hepatology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
  • Department of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China.
  • Henan Institute of Advanced Technology, Zhengzhou University, Zhengzhou 450003, China.
  • Department of Nutrition and Food Hygiene, School of Public Health, Capital Medical University, Beijing 100069, China.
  • CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety & CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, 11 Beiyitiao, Zhongguancun, Beijing 100190,…

ORCID profiles: Yingqiu Qi, Huan Min, Guangjun Nie, Hongxia Liang

Funding

  • Ministry of Science and Technology of the People's Republic of China
  • Zhengzhou University
  • National Natural Science Foundation of China
  • Henan Province
  • Finance Bureau of Henan Province

Cite

APA

Liu, H., Qi, Y., Wang, L., Zhang, Y., Chen, H., Zhao, Y., Min, H., Nie, G., & Liang, H. (2025). Lysosome-Targeting Nanochimeras Attenuating Liver Fibrosis by Interconnected Transforming Growth Factor-β Reduction and Activin Receptor-Like Kinase 5 Degradation. ACS Nano. https://doi.org/10.1021/acsnano.5c00985

Vancouver

Liu H, Qi Y, Wang L, Zhang Y, Chen H, Zhao Y, et al. Lysosome-Targeting Nanochimeras Attenuating Liver Fibrosis by Interconnected Transforming Growth Factor-β Reduction and Activin Receptor-Like Kinase 5 Degradation. ACS Nano. 2025. doi:10.1021/acsnano.5c00985

BibTeX
@article{Liu2025,
  author = {Liu, Hanshu and Qi, Yingqiu and Wang, Longdi and Zhang, Yana and Chen, Hanqing and Zhao, Ying and Min, Huan and Nie, Guangjun and Liang, Hongxia},
  title = {Lysosome-Targeting Nanochimeras Attenuating Liver Fibrosis by Interconnected Transforming Growth Factor-β Reduction and Activin Receptor-Like Kinase 5 Degradation},
  journal = {ACS Nano},
  year = {2025},
  doi = {10.1021/acsnano.5c00985}
}
Start for free →